Anabolic agents for treating postmenopausal osteoporosis

Joint Bone Spine

Volumn 68, Issue 6, 2001, Pages 576-581

  Meunier, Pierre J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; CALCITONIN; CALCIUM; ESTROGEN DERIVATIVE; FLUORIDE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SOMATOMEDIN; STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR NECK; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; SHORT SURVEY; VERTEBRA FRACTURE;

EID: 0035673870     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(01)00329-3     Document Type: Short Survey

References (43)

1. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: 3 Years of blinded therapy followed by one year of open therapy
2. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
3. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture
4. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis
5. Effect of risedronate on the risk of hip fracture in elderly women
6. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
7. Prospective, randomized trial of nasal spray calcitonin in postmenopausal women with established osteoporosis: The proof study
8. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women
9. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
10. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis
11. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
12. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOS study
13. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized controlled trial
14. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: Dose related effects on bone density and fracture rate
15. Serum levels of IGF-I, IGFBP-2 and IGFBP-3 in osteoporotic patients with and without spine fractures
16. Low serum IGF-I but not IGFBP-3 predicts hip and spine fracture: The study of osteoporotic fracture abstract
17. IGF-I and aging: A new perspective for a new century
18. Anabolic therapy for osteoporosis. Clinical review 123
19. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis. A multicentre trial
20. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds
21. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone
22. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
23. PTH: Mechanism of action
24. Human PTH increases rat bone mass in ovariectomized and orchidectomized rats
25. Increased bone formation by prevention of osteoblast apoptosis with PTH
26. PTH restores bone mass and enhances osteoblast IGF-I gene expression in ovariectomized rats
27. Response of cortical bone to antiresorptive agents and PTH in aged ovariectomized rats
28. Cyclical treatment of osteopenic ovariectomized adult rats with PTH (1-34) and pamidronate
29. Restoration of spine bone mass in osteoporotic men by treatment with hPTH and 1,25 vitamin D
30. Therapy of idiopathic osteoporosis in men with parathyroid hormone: Effects on bone mineral density and bone markers
31. Enhancement of bone mass in osteoporotic women with PTH followed by alendronate
32. Randomized controlled study of the effect of PTH on vertebral bone mass and fracture incidence among post-menopausal women on oestrogen with osteoporosis
33. Parathyroid hormone 1-34 and estrogen produce dramatic bone density increases in postmenopausal osteoporosis. Results from a placebo-controlled randomized trial
34. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate
35. Stimulation of bone formation in vitro and in rodents by statins
36. Statins and increased bone mineral density in postmenopausal women
37. HMG-CoA reductase inhibitors and the risk of fractures
38. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
39. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
40. Use of statins and risk of fractures
41. The effect of fluvastatin on parameters of bone remodeling
42. The divalent salt 12 911 enhances bone replication and bone formation in vitro
43. Strontium ranelate as a treatment of vertebral osteoporosis